2. The costs of lawsuit shall be borne by the Plaintiff.

A. On June 20, 2010, the Plaintiff was enrolled in the New Village Synae Hospital (hereinafter “Defendant Hospital”) operated by the Defendant on July 9, 2010 while receiving the diagnosis and treatment of the blood plate decline by Esar Masar Masar, and the medical personnel at the Defendant Hospital confirmed that the blood plate of the Plaintiff was reduced due to blood examination by the Plaintiff.

Accordingly, on August 12, 2010 and November 11, 2011 of the same year, the medical personnel at Defendant Hospital explained that the Plaintiff may perform influorite medication without any response to pharmacologic treatment, and explained that the Plaintiff may perform influorite medication, and confirmed the change of the Plaintiff’s condition by administering deficiency influorine as response to the reduction of pharmacologic values.

B. From January 3, 2011, the Plaintiff was hospitalized in the Defendant Hospital on January 201, 201, because there was symptoms of well-beinging snow from around January 3, 201 to around January 11, 201, and was diagnosed with a free body blood transfusion and received treatment. On January 20, 2011, the Plaintiff was hospitalized in the Defendant Hospital. As the Plaintiff’s symptoms of decrease in the dial health care, the medical personnel of the Defendant Hospital administered an immunologically to the Plaintiff by January 21, 201, and from January 22, 2011 to January 22, 2011.

1. By 25.25. As a result of the implementation of the High Concentration Rotterdam, the blood plate value increased up to 85,000.

However, on January 28, 201, the medical personnel of the defendant hospital seems to have reduced the plaintiff's blood plate value by 15,000, and judged that the plaintiff's non-compliance with the immunological health care is the plaintiff's non-compliance with the immunological health care, and then the medical personnel of the defendant hospital decided to implement the immunological health care in the next stage.

C. Accordingly, from January 28, 2011, the Defendant hospital began to administer Ciplosporine-N (hereinafter “Lol”) which is an exempted control (hereinafter “Cyclosporine”) to the Plaintiff, the body of which was 73km. As a result of the blood concentration test, the Defendant hospital confirmed that the blood concentration was increased on January 31, 201, on February 7, 201, and that the blood concentration was increased by approximately 6mg/ml on February 1941.